PROVIDENCE-STRATEGIC
11.9.2020 10:01:09 CEST | Business Wire | Press release
Imaweb/ IDF Group, a leading independent provider of customer relationship management (“CRM”) solutions and dealership management systems (“DMS”) for the automotive industry in Europe, today announced that it has completed its acquisition of TMS-Soft, a leading provider of digital car registration workflow software in France. Imaweb/ IDF Group is backed by Providence Strategic Growth (“PSG”), the growth equity affiliate of premier asset management firm Providence Equity Partners (“Providence”). Financial terms were not disclosed.
Founded in 2008, TMS-Soft automates and streamlines processes associated with vehicle registration through its cutting-edge, digital platform. The company is the largest of only three non-governmental organizations authorized to issue vehicle registration credentials under the French system, the système d'immatriculation des véhicules (SIV). TMS-Soft’s team serves over 3,700 clients ranging from used car dealerships, auto centers, and online car sales marketplaces.
Patrick Prajs, CEO of Imaweb/ IDF Group, said, “Our acquisition of TMS-Soft will enable us to offer clients a highly valuable add-on to their existing suite of Imaweb/IDF Group products, which are centered around our core CRM and DMS products. We will also be able to reach a broader base of customers – especially used-car dealerships – across all our markets. Today’s announcement is a testament of the momentum we have sustained since partnering with PSG, and we are optimistic about the road ahead. We are pleased to welcome the TMS-Soft team to our family and look forward to working together as we solidify our position as a leading European provider of CRM, DMS, and now digital workflow solutions for the automotive industry in Europe.”
Lionel Amrouche, Founder and CEO of TMS-Soft, said, “This transaction underscores the strength of the TMS-Soft brand and importance of our offering. We are excited for the future and look forward to growing the business under the Imaweb/ IDF Group umbrella.”
Since its formation following PSG’s investment in September 2019, Imaweb/ IDF Group has become one of Europe’s premier full-service providers of automotive CRM, DMS and other digital solutions. In the last 12 months, Imaweb/ IDF Group has also completed the acquisitions of ITMotive, a Netherlands-based distributor and servicer of DMS in the Benelux region, and Serinfer, the computer software segment of the Alvariño Group, a Spanish developer, distributor and supplier of DMS.
Imaweb/ IDF Group
Imaweb/ Datafirst-I’Car Systems Group (“Imaweb/ IDF Group”) is a leading developer of CRM and DMS solutions for the automotive sector in Europe. The company was formed through the merger of Imaweb, a Spanish company dedicated to developing global customer management solutions for sales, marketing and after-sales, and DATAFIRST-I’Car Systems, a French software development company for car manufacturers, groups distribution and dealers, in 2019.
TMS-Soft
TMS-Soft is one of only three non-governmental organizations authorized to issue vehicle registration credentials under the French system, the système d'immatriculation des véhicules (SIV). Through its digital platform, TMS-Soft facilitates all formalities associated with the registration process, with a focus on used vehicle registration. TMS-Soft was founded in 2008 by Lionel Amrouche, who continues to lead the business, and is powered by a team serving over 3,700 clients. Please visit https://www.tms-soft.fr/ for more information.
Providence Strategic Growth
PSG is an affiliate of Providence Equity Partners (“Providence”). Established in 2014, PSG focuses on growth equity investments in lower middle market software and technology-enabled service companies. Providence is a premier global asset management firm that pioneered a sector-focused approach to private equity investing with the vision that a dedicated team of industry experts could build exceptional companies of enduring value. Since the firm’s inception in 1989, Providence has invested in more than 200 companies and is a leading equity investment firm focused on the media, communications, education, software and services industries. PSG is headquartered in Boston, MA, with offices in London and Kansas City. For more information on PSG, please visit https://www.provequity.com/private-equity/psg , and for more information on Providence, please visit https://www.provequity.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200911005129/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom